Manager TitleAgeSince
Director of Finance/CFO 62 2017-02-28
Chief Tech/Sci/R&D Officer - -
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 50 2019-11-20
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+0.61% - - 403M
+1.18%-1.28%-16.90%+10.73% 188B
+1.85%+1.04%+7.29%+38.96% 126B
-0.88%-4.98%-14.52%+9.17% 118B
+1.26%-3.12%-41.49%+3.81% 92.48B
+2.76%+7.64%-0.80%+85.81% 68.51B
+1.08%+2.90%+12.95%-6.73% 59.39B
+0.89%+4.17%+2.07%+52.91% 55.48B
-2.26%+0.86%-2.24%+42.81% 49.62B
+1.76%+2.16%+1.86%+0.45% 35.17B
Average +0.76%+1.11%-5.75%+26.44% 79B
Weighted average by Cap. +0.91%+0.03%-8.86%+23.87%

Financials

2017 2018
Net sales 20.15M 18.26M 16.89M 15.24M 28.72M 1.9B 29.74M 203M 80.46M 1.02B 75.63M 74.03M 3.22B 27.67M 25.08M 23.19M 20.93M 39.44M 2.61B 40.83M 279M 110M 1.39B 104M 102M 4.42B
Net income -21.28M -19.28M -17.83M -16.09M -30.32M -2.01B -31.39M -214M -84.95M -1.07B -79.85M -78.15M -3.4B -25.12M -22.77M -21.06M -19M -35.8M -2.37B -37.06M -253M -100M -1.27B -94.28M -92.28M -4.02B
Net Debt - -
Logo Avedro, Inc.
Avedro Inc is a United States-based company. The Company is an ophthalmic pharmaceutical and medical device company developing and commercializing a suite of products based on its corneal collagen cross-linking technology platform to address a wide variety of ophthalmic disorders and conditions, primarily associated with corneal weakness. Its primary components of the Avedro Cross-Linking Platform are pharmaceutical formulations of riboflavin (vitamin B2), a ‘single dose pharmaceutical,’ sold primarily in conjunction with the Company’s innovative devices for the delivery of metered doses of ultraviolet (UVA) light, a medical device.
Employees
-
  1. Stock Market
  2. Stocks
  3. AVDR Stock